Phase 4 N=8

Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis

Acute Kidney Failure

Bottom Line

View on ClinicalTrials.gov: NCT00877370 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Sep 2012

Primary outcome: Primary: Ertapenem Transmembrane Clearance by Continuous Hemodialysis. — 10.4 mL/min

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: ertapenem (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Michigan
Primary completion: Mar 2011

Outcome Measures

Outcome	Result	p-value
PRIMARY Ertapenem Transmembrane Clearance by Continuous Hemodialysis.	10.4	—

Summary

Critically ill patients in the intensive care unit often receive continuous hemodialysis to treat their kidney failure. Ertapenem is an antibiotic often used in these patients. Continuous dialysis may remove ertapenem, putting patients at risk for inappropriate treatment of their infection. This study will determine how much ertapenem is removed by continuous hemodialysis.

Eligibility Criteria

Inclusion Criteria

Hospitalized in ICU
Receiving Continuous hemodialysis
Prescribed ertapenem
Informed consent granted

Exclusion Criteria

< 18 years of age
Allergy to ertapenem or other carbapenem antibiotic
Severe, life-threatening reaction to penicillin or cephalosporins
Patients experiencing or with history of CNS disorders (eg: seizure, stroke)
Patients experiencing CNS infection
Inability to complete 24 hours of CVVHD
Concurrent use of other extracorporeal therapies such as extracorporeal membrane oxygenation, plasmapheresis or intermittent hemodialysis
Inability to obtain informed consent
Pregnant and/or breastfeeding women

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00877370). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.